FDA Import Refusal AEK-5501837-6/11/1 — AstraZeneca Canada Inc.
The FDA refused shipment AEK-5501837-6/11/1 from AstraZeneca Canada Inc. (Canada) on Aug 2, 2024. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal details
- Date
- Aug 2, 2024
- Country
- Canada
- Product Category
- Drugs and Biologics
- Product Code
- 61PDY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75